Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.